Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie Inc. and Jazz Pharmaceuticals.

Medical Crossfire®: Uncovering the Potential Impact of Emerging Data and Ongoing Clinical Trials in AML

Release Date: August 30, 2019
Expiration Date: August 30, 2020
Media: Internet - based

Activity Overview

To optimize outcomes for patients with acute myeloid leukemia (AML), healthcare practitioners need both access to emerging clinical data and expert guidance on how to utilize these data to optimize patient care. Numerous practice-changing developments were recently made in AML. The increase in understanding of the genetics of AML and disease-related factors has led to the development of risk stratification models to help predict the clinical course for a given patient and aid in planning a therapeutic approach. New therapy approvals in AML have rapidly altered treatment paradigms, and other agents are being evaluated in clinical trials. This advancement in treatment innovation has resulted in important competence gaps among practitioners who must decipher the best course of patient management to achieve optimal clinical outcomes. Prevention of disease relapse and improvement of clinical outcomes for patients who experience relapsed/refractory AML is a primary concern. Practitioners have a critical need to be familiar with how to apply recent data for available agents, including how to monitor for and manage treatment-related toxicities.

To help you meet this challenge, this Medical Crossfire® will feature a series of case presentations given by prominent experts in the field to discuss the latest data in AML and the implications for clinical practice. In addition to clinical scenarios, the expert panel will highlight the emerging data for immunotherapeutic agents for AML, provide expert guidance on the interpretation of core concepts, and explore optimal selection of evolving targeted therapy options in AML.


Benefits of Participating

  • Utilize insight from leading clinical experts to personalize targeted therapy for patients
  • Discuss challenging clinical cases with Dr. Martin Tallman, Vice President of the ASH Executive Committee
  • Implement strategies that support best practice care that is at the forefront of treatment advances in AML
  • Solidify protocols for treatment selection for complex clinical settings, such as older patients with AML who have poor performance status
  • Explore possible opportunities to enroll patients with AML into clinical trials through discussion with well-known clinical trial investigators
  • Network with your colleagues who have different levels of experience with targeted therapy and clinical trial design in AML

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie Inc. and Jazz Pharmaceuticals.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Video” will be available for your reference.
  • In order to receive a CME/CE Certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE Certificate upon completion of these steps.

Target Audience

These activities are intended for medical oncologists, hematologists, and other oncology healthcare professionals interested in the latest advances in the treatment of patients with acute myeloid leukemia.

Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with acute myeloid leukemia are also invited to attend.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Identify testing strategies to stratify risk among patients with AML, methods to apply results from these tests, and ongoing monitoring strategies for patients with these tumors
  • Describe results from recent clinical trials that have evaluated current and emerging treatment strategies among patients with AML
  • Apply novel treatment approaches in the context of evolving treatment paradigms in the management of AML including methods to personalize care for elderly patients or those with poor performance status
  • Delineate approaches to proactively manage treatment-related toxicities that occur along the disease continuum in the care of patients with AML

Faculty, Staff, and Planners’ Disclosures


Saad Zafar Usmani
Martin Tallman, MD
Chief, Leukemia Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

Disclosures: Grant/Research Support: AbbVie, Celierant, Orsenix, ADC Therapeutics, Biosight; Consultant: Abbvie, BioLine Rx, Daiichi-Sankyo, Orsenix, AKAHR, Rigel, Nohla, Delta Fly Pharma, Tetraphase, Oncolyze, Jazz Pharma. Other Support: UpTpDate roaylties.

Earle Burgess
Alexander Perl, MD
Associate Professor of Medicine
Division of Hematology/Oncology
Perelman School of Medicine
Leukemia Program
Hospital of the University of Pennsylvania
Philadelphia, PA

Disclosures: Grant/Consultant Support: Actinium Pharmaceuticals, Astellas, Daiichi Sankyo, FujiFilm, Novartis (all grants/support to institution); Consultant: Astellas, Daiichi Sankyo, Arog, AbbVie; Other Support: Honoraria: AbbVie, Actinium, Agios, Astellas, Daiichi Sankyo, NewLink Genetics, Takeda

Stephanie L. Graff
James McCloskey, MD
Interim Chief, Division of Leukemia
John Theurer Cancer Center
Hackensack University Medical Center
Hackensack, NJ

Disclosures: Consultant: Jazz, Pfizer; Speaker’s Bureau: Jazz, Celgene, AbbVie

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COIs. PER® has identified and resolved all COIs prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By